Unicycive Therapeutics, Inc., (UNCY): Price and Financial Metrics


Unicycive Therapeutics, Inc., (UNCY): $0.56

0.01 (+2.38%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add UNCY to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

UNCY Stock Price Chart Interactive Chart >

Price chart for UNCY

UNCY Price/Volume Stats

Current price $0.56 52-week high $1.64
Prev. close $0.55 52-week low $0.40
Day low $0.51 Volume 109,589
Day high $0.60 Avg. volume 171,440
50-day MA $0.63 Dividend yield N/A
200-day MA $0.74 Market Cap 8.43M

Unicycive Therapeutics, Inc., (UNCY) Company Bio


Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.


UNCY Latest News Stream


Event/Time News Detail
Loading, please wait...

UNCY Latest Social Stream


Loading social stream, please wait...

View Full UNCY Social Stream

Latest UNCY News From Around the Web

Below are the latest news stories about UNICYCIVE THERAPEUTICS INC that investors may wish to consider to help them evaluate UNCY as an investment opportunity.

Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation''s Spring Clinical Meetings

LOS ALTOS, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ: UNCY ), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that three abstracts have been accepted for presentation at the National Kidney Foundation''s (NFK) upcoming Spring Clinical Meetings taking place in Austin, Texas from April 11-15, 2023. The following data will be presented at the NFK''s Spring Clinical Meeting: Results from three pre-clinical studies of UNI-494, evaluating the risk of drug/drug interactions (DDI) will be presented in a poster titled, "In Vitro Drug Interaction Studies of UNI-494 Indicate Low Risk of Drug-Drug Interactions." Efficacy data from a study of UNI-494 in a bilateral renal ischemia perfusion (I/R) model ...

Benzinga | January 23, 2023

Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings

Data support UNI-494’s potential to treat acute kidney disease and underscore the phosphate binding benefits of Renazorb as a potential treatment for hyperphosphatemiaLOS ALTOS, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that three abstracts have been accepted for presentation at the National Kidney Foundation’s (NFK) upcoming Spring Clinical M

Yahoo | January 23, 2023

Why Unicycive Therapeutics Inc. (NASDAQ: UNCY) Stock Shouldn’t Be Ignored In 2023

In the last trading session, 0.18 million shares of the Unicycive Therapeutics Inc. (NASDAQ:UNCY) were traded. Most recently the company’s share price was $0.50, and it changed around -$0.04 or -8.33% from the last close, which brings the market valuation of the company to $8.19M. UNCY currently trades at a discount to its 52-week high … Why Unicycive Therapeutics Inc. (NASDAQ: UNCY) Stock Shouldn’t Be Ignored In 2023 Read More »

Marketing Sentinel | January 16, 2023

Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023

Growing body of clinical evidence support the potential of Renazorb and UNI-494 to effectively treat hyperphosphatemia and acute kidney disease, respectivelyLOS ALTOS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that four abstracts have been accepted for presentation at the upcoming International Society of Nephrology’s World Congress of Nephrol

Yahoo | January 5, 2023

Unicycive Therapeutics Inc. (UNCY) is an excellent investment, but the stock is overvalued/undervalued right now

The share price of Unicycive Therapeutics Inc. (NASDAQ:UNCY) fell to $0.54 per share on Friday from $0.56. While Unicycive Therapeutics Inc. has underperformed by -3.57%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, UNCY fell by -73.66%, with highs and lows ranging from $2.35 to $0.40, […]

US Post News | January 3, 2023

Read More 'UNCY' Stories Here

UNCY Price Returns

1-mo 3.70%
3-mo -18.98%
6-mo -25.33%
1-year -59.42%
3-year N/A
5-year N/A
YTD 3.70%
2022 -73.79%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7103 seconds.